First Quarter 2018 Investor Presentation

Investor Presentation First three months of 2018 Slide 93 Novo Nordisk maintains leadership within growth disorder Development in global growth disorder market DKK billion 20 15 10 5 0 Feb 2013 MAT volume kg CAGR volume¹: 14.3% CAGR value DKK¹: 18.8% 1 CAGR for 5-year period Source: IQVIA monthly MAT Feb, 2018 volume figures and value (DKK) figures changing diabetes® Growth disorder volume market share MAT value DKK kg 100 35% 30% 80 25% 60 20% 40 15% 10% 20 5% 0 0% Feb Feb 2018 2013 Novo Nordisk Eli Lilly Source: IQVIA monthly MAT Feb, 2018 volume figures Pfizer Merck Kgaa Sandoz 27% Feb 2018 novo nordisk

View entire presentation